PDF) Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: The HELIOS study

Por um escritor misterioso
Last updated 15 junho 2024
PDF) Real-world variability in ranibizumab treatment and associated  clinical, quality of life, and safety outcomes over 24 months in patients  with neovascular age-related macular degeneration: The HELIOS study
PDF) Real-world variability in ranibizumab treatment and associated  clinical, quality of life, and safety outcomes over 24 months in patients  with neovascular age-related macular degeneration: The HELIOS study
Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
PDF) Real-world variability in ranibizumab treatment and associated  clinical, quality of life, and safety outcomes over 24 months in patients  with neovascular age-related macular degeneration: The HELIOS study
Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial
PDF) Real-world variability in ranibizumab treatment and associated  clinical, quality of life, and safety outcomes over 24 months in patients  with neovascular age-related macular degeneration: The HELIOS study
PDF) Visual Acuity Outcomes and Anti-Vascular Endothelial Growth Factor Therapy Intensity in Neovascular AMD Patients: A “Real World” Analysis in 49,485 Eyes
PDF) Real-world variability in ranibizumab treatment and associated  clinical, quality of life, and safety outcomes over 24 months in patients  with neovascular age-related macular degeneration: The HELIOS study
Long-term outcomes of intravitreal anti-VEGF therapies in patients affected by neovascular age-related macular degeneration: a real-life study, BMC Ophthalmology
PDF) Real-world variability in ranibizumab treatment and associated  clinical, quality of life, and safety outcomes over 24 months in patients  with neovascular age-related macular degeneration: The HELIOS study
A prospective, observational, open‐label, multicentre study to investigate the daily treatment practice of ranibizumab in patients with neovascular age ‐related macular degeneration - Asten - 2015 - Acta Ophthalmologica - Wiley Online Library
PDF) Real-world variability in ranibizumab treatment and associated  clinical, quality of life, and safety outcomes over 24 months in patients  with neovascular age-related macular degeneration: The HELIOS study
Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records - ScienceDirect
PDF) Real-world variability in ranibizumab treatment and associated  clinical, quality of life, and safety outcomes over 24 months in patients  with neovascular age-related macular degeneration: The HELIOS study
Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration
PDF) Real-world variability in ranibizumab treatment and associated  clinical, quality of life, and safety outcomes over 24 months in patients  with neovascular age-related macular degeneration: The HELIOS study
Longer treatment intervals are associated with reduced treatment persistence in neovascular age related macular degeneration
PDF) Real-world variability in ranibizumab treatment and associated  clinical, quality of life, and safety outcomes over 24 months in patients  with neovascular age-related macular degeneration: The HELIOS study
Determinants of visual acuity outcomes in eyes with neovascular AMD treated with anti-VEGF agents: an instrumental variable analysis of the AURA study
PDF) Real-world variability in ranibizumab treatment and associated  clinical, quality of life, and safety outcomes over 24 months in patients  with neovascular age-related macular degeneration: The HELIOS study
Ranibizumab reimbursement and treatment patterns for neovascular age-related macular degeneration in Taiwan – Results from the 12-month, observational RENOWNED study - ScienceDirect
PDF) Real-world variability in ranibizumab treatment and associated  clinical, quality of life, and safety outcomes over 24 months in patients  with neovascular age-related macular degeneration: The HELIOS study
Biomolecules, Free Full-Text
PDF) Real-world variability in ranibizumab treatment and associated  clinical, quality of life, and safety outcomes over 24 months in patients  with neovascular age-related macular degeneration: The HELIOS study
The management of neovascular age‐related macular degeneration: A systematic literature review of patient‐reported outcomes, patient mental health and caregiver burden - Gale - 2023 - Acta Ophthalmologica - Wiley Online Library
PDF) Real-world variability in ranibizumab treatment and associated  clinical, quality of life, and safety outcomes over 24 months in patients  with neovascular age-related macular degeneration: The HELIOS study
Correlation between improvement in visual acuity and QOL after Ranibizumab treatment for age-related macular degeneration patients: QUATRO study, BMC Ophthalmology
PDF) Real-world variability in ranibizumab treatment and associated  clinical, quality of life, and safety outcomes over 24 months in patients  with neovascular age-related macular degeneration: The HELIOS study
PDF) Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: The HELIOS study
PDF) Real-world variability in ranibizumab treatment and associated  clinical, quality of life, and safety outcomes over 24 months in patients  with neovascular age-related macular degeneration: The HELIOS study
Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records - ScienceDirect

© 2014-2024 praharacademy.in. All rights reserved.